Partners
Axxam has built a growing network of scientific partners, including industry leaders and innovative research organizations, to enhance its service offering and provide clients with complementary expertise for the identification and validation of bioactive molecules across all life sciences industries.
Discover each of our trusted partners and contact us to learn more how we collaborate.Scientific and Business Partners
BiomimX is a pioneer in Organ-on-a-Chip (OoC) technology, dedicated to transforming pharmaceutical drug discovery through clinically relevant in vitro models. At the core of their innovation is the proprietary uBeat® platform, which integrates microfluidics, 3D human cell cultures, and controlled mechanical stimulation. This unique approach produces “Beating OoCs” that replicate human pathophysiology with unprecedented precision.
Its flagship uHeart model is a functional heart-on-chip enabling the assessment of electrical and contractile cardiac liabilities in human 3D tissue. The uBeat® platform also powers a growing pipeline including uKnee (osteoarthritis), uScar (cardiac fibrosis), and models for gut, lung and multi-organ applications.
BiomimX enables faster, cost-effective, and ethical drug development, positioning itself as a key leader in the global shift toward predictive non-animal testing.
www.biomix.com
B’SYS GmbH is a Swiss-based CRO specializing in ion channel pharmacology at the intersection of cellular electrophysiology and preclinical drug development. Its validated portfolio of human ion channel-expressing cell lines is supported by a suite of in vitro platforms, including manual and automated patch clamp, fluorescence-based screening, and CiPA-compliant assays. B’SYS provides GLP-compliant studies and licenses ion channel reagents to support discovery and profiling efforts. With expertise in target validation, safety pharmacology and assay development, B’SYS contributes to safer, more effective therapeutics and advances next-generation bioactives across health, nutrition, recreation, and environmental applications.
www.bsys.ch
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of
human induced pluripotent stem cells (hiPSCs) utilized in drug discovery and cell
therapies. FCDI offers life science research tools including the company’s inventoried
iCell® products that are available in many cell types and sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and integrated drug discovery services with partners. FCDI’s goal is to leverage the vast utility of hiPSCs to advance human health and improve the quality of life for patients around the world.
www.fujifilmcdi.com
HeartBeat.bio AG is a pioneering TechBio company developing breakthrough therapies for heart failure through its next-generation Cardioid Drug Discovery Platform. This proprietary platform integrates iPSC-derived cardiac organoids with advanced automation and AI-driven analytics to enable scalable, human-centric drug discovery. Utilizing physiologically relevant and scalable human model systems, HeartBeat.bio enhances translational predictability, shortens development timelines, and reduces clinical failure rates.
The company is advancing its own therapeutic pipeline while strategically partnering with pharma and biotech companies to co-develop transformative heart failure treatments. Initial focus areas include cardiomyopathies, myocardial fibrosis, and its effects on cardiac remodeling, a chronic disease phenotype prevalent in most heart failure patients.
www.heartbeat.bio
Isogenica is a specialist partner in small-format antibody discovery. In particular, VHH-single-domain antibodies or “nanobodies” that offer exceptional robustness, flexibility, and scalability across varied therapeutic and diagnostic applications. Combining the world’s largest synthetic VHH libraries with proprietary display technology allows screening of 1000x more antibodies with greater precision, increasing the chance of finding the perfect fit. Partnership with Axxam combines both small molecule and antibody discovery services, offering streamlined services for innovative partners in global biotech and pharma. Beyond these capabilities, both companies are united by shared values of integrity, clear communication, and a true passion for science.
www.isogenica.com
Founded in 2015 as a spin-out from the Paul Scherrer Institute (ETH), leadXpro is located in Switzerland, between the pharma and science hubs of Basel and Zürich. leadXpro is revolutionising drug discovery for membrane proteins, targeting GPCRs, ion channels and transporters. These proteins represent more than half of clinically-used current drug targets, but remain the most difficult targets for structure-based drug design, due to the challenges in solving their atomic structures in complex with drug candidates. leadXpro combines state-of-the-art methods for membrane protein science, advanced biophysical methods to characterize drug candidate interactions and pioneering technologies in structural biology, including cryo-EM and time-resolved X-ray crystallography at SwissFEL.
www.leadxpro.com
Lucera is a Heidelberg, Germany-based technology company focused on supporting decision intelligence by applying advanced data integration and artificial intelligence in pharmaceutical research and development. The company builds on a long-standing foundation of proprietary data, expert curation, and advanced analytics, including a semantically integrated knowledge base – Dataome® – developed over more than 15 years.
Lucera’s platform addresses high-stake questions across target and mechanism validation, indication prioritization, biomarker and patient stratification, translational evidence strategy, clinical and real-world evidence interpretation, trial design considerations, clinical trial simulation and asset and portfolio due diligence which builds on Dataome®’s strong medical and biology context and quality.
Momentum Biotechnologies is a drug discovery partner providing specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. Thanks to their proven workflows, state-of-the-art facilities, and extensive mass spectrometry experience, Momentum is uniquely positioned to deliver rapid, reliable answers to a wide range of pressing research questions.
www.momentum.bio
Neuro-Zone S.r.l. is an innovation driven cell-based service company supporting drug
discovery, drug repurposing and research projects in the fields of inflammation and
age-related pathologies. Neuro-Zone aims to unveil the role of the microenvironment in complex disease scenarios through unique proprietary technological solutions, with the goal of easing lead efficacy assessment. Neuro-Zone activities enable collection of rapid and informative data on efficacy, toxicity, metabolism and mechanism of action. Moreover, they enable effective selection and ranking of the most promising candidates per indication.
www.neuro-zone.com
Opertech Bio is a leader in taste measurement technology, catering to the food and beverage, flavor ingredient, and pharmaceutical industries. Opertech’s innovative TāStation® system (taste + station) revolutionizes sensory evaluation by gamifying the process and enhancing throughput. Featuring a unique human-machine interface, TāStation® seamlessly integrates human taste perception with advanced automation and data analysis. Unlike traditional methods, TāStation® provides highly reliable and statistically precise data, significantly increasing efficiency, improving participant engagement, and reducing costs. This empowers companies to uncover new flavor ingredients, assess palatability, and optimize flavor formulations.
www.opertechbio.com
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.
www.promega.com
Symeres is a leading European contract research organization for drug discovery and
development projects. Their services span from early-stage hit finding all the way to the delivery of Phase II API and customised in vitro and in vivo ADME-Tox packages.
The partnership between Symeres and Axxam gives our clients access to best-in-class
fully integrated drug discovery services, supported by a culture of scientific excellence, innovation and creativity.
www.symeres.com
Tessara Therapeutics is a Melbourne-based biotechnology company pioneering RealBrain®, a human-relevant 3D neural micro-tissue platform designed to transform neurological drug discovery. Tessara’s “mini-brains” replicate key structural and functional features of human brain tissue, enabling more predictive screening of drug candidates for neurodegenerative and other neurological conditions. Tessara combines advances in tissue engineering, biomaterials, automation, data science and artificial intelligence to create scalable, reproducible and clinically relevant models of the human brain. Its RealBrain® platform supports drug efficacy, toxicity and disease-modelling studies, helping pharmaceutical and biotechnology companies generate deeper insights earlier in the development process.
www.tessaratx.com
X-Chem is a global leader in DNA-encoded library (DEL) technology and small molecule discovery. With a proprietary DEL platform exceeding 200 billion compounds, X-Chem has supported over 100 partnered programs and delivered 15 clinical candidates to date. The company combines AI-driven hit identification, structure-based design, and medicinal chemistry to tackle challenging targets and modalities. X-Chem offers flexible, scalable partnerships that integrate computational and experimental insights to reduce risk and accelerate discovery timelines.
www.x-chemrx.com
ZoBio offers an integrated fragment-based drug discovery engine based on orthogonal technologies and 16 years of experience. Located in the Netherlands, ZoBio delivers the right small molecule for your target by combining its expertise in protein sciences, biophysical and biochemical assays, structural biology and medicinal chemistry.
www.zobio.com
Associations
Lombardy Life Sciences Cluster
Association
